1. Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. Issue 24 (20th August 2021) Authors: Olson, Daniel J.; Eroglu, Zeynep; Brockstein, Bruce; Poklepovic, Andrew S.; Bajaj, Madhuri; Babu, Sunil; Hallmeyer, Sigrun; Velasco, Mario; Lutzky, Jose; Higgs, Emily; Bao, Riyue; Carll, Timothy C.; Labadie, Brian; Krausz, Thomas; Zha, Yuanyuan; Karrison, Theodore; Sondak, Vernon K.; Gajewski, Th... Journal: Journal of clinical oncology Issue: Volume 39:Issue 24(2021) Page Start: 2647 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Personalized Management of Chemotherapy‐Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance). (4th December 2019) Authors: Sharma, Manish R.; Mehrotra, Shailly; Gray, Elizabeth; Wu, Kehua; Barry, William T.; Hudis, Clifford; Winer, Eric P.; Lyss, Alan P.; Toppmeyer, Deborah L.; Moreno‐Aspitia, Alvaro; Lad, Thomas E.; Velasco, Mario; Overmoyer, Beth; Rugo, Hope S.; Ratain, Mark J.; Gobburu, Jogarao V. Journal: Journal of clinical pharmacology Issue: Volume 60:Number 4(2020) Page Start: 444 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗